A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

RedBrick AI Raises US$4.6M

To accelerate the development of healthcare AI

Health-tech AI platform RedBrick AI is today announcing a US$4.6M seed funding round to accelerate the development and adoption of artificial intelligence in clinical settings, through rapid data annotation on medical imagery. The round was led by Surge, Sequoia Capital India, and Southeast Asia’s rapid scale-up program, with participation from Y Combinator and angels.

Medical imagery is an essential source of truth in clinical diagnosis and comprises about 90% of all healthcare data. AI systems can dramatically shorten the time to diagnosis, improve clinician productivity by triaging high-importance cases, and act as the first line of defense in under-staffed clinical environments.

Researchers and healthcare institutions are increasingly investing in AI solutions to improve diagnostics, treatment and patient quality of care. The use of AI in healthcare stands to transform patient care by boosting clinician productivity and automating clinical diagnosis. In 2021 alone, the U.S. Food and Drug Administration (FDA) approved 115 AI algorithms for use in medical environments, an 83% increase from 2018.

However, researchers cannot use medical images to train AI systems until they are cleaned and expertly annotated. Training an AI system also requires hundreds of annotated medical images and thousands of hours of annotation by clinicians. Due to the complexity, size, and unique nature of medical images, clinicians have to resort to traditional and difficult-to-use clinical tools to perform annotations.

RedBrick AI is thus laser focused on solving the first key challenge to healthcare AI adoption – providing clinicians high-quality data annotation tools that accelerate the preparation of training datasets.

RedBrick AI CEO and co-founder Shivam Sharma commented: “Working with leading healthcare AI teams over the past year has been an incredible journey and learning opportunity. With the rapid growth of artificial intelligence in clinical settings, researchers need excellent tools to build high-quality datasets and models at scale. Our customers are in the vanguard of this growth, pioneering everything from surgical robots to automated detection of cancers. We are incredibly excited to use the funds we’ve raised to power the next generation of researchers in building AI for clinical settings.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

With this new investment partnership, E Tech Group expects to accelerate organic growth and acquisition to become a top system integrator in North America.
The investment will allow ROM InWest to further distribute its fall detection product globally.
Nawal Ouzren, Sensorion’s Chief Executive Officer, said: “We are thrilled to announce another successful capital raise, securing an additional EUR 15 million to accommodate interest expressed by certain existing investors. This builds on the earlier EUR 50 million financing announced in February 2024, adding up to a total of EUR 100 million raised in less than 9 months. With this new financing, we are well-positioned to accelerate our gene therapy programs, including the progression of SENS-501 through its Phase 1/2 clinical study, Audiogene, and the advancement of our second program, GJB2-GT, towards Clinical Trial Applications submission in H1 2025. The capital increase enables the Company to finance its activities until the end of 2025. We remain deeply thankful for the ongoing support of our shareholders and partners as we strive to make a meaningful difference in the lives of those affected by hearing loss disorders.”
Strategic Investor, Osang Healthcare will partner with Kryptos Biotechnologies for the manufacturing and distribution of the product along with financing.
Proceeds from the financing will advance Obsidian’s lead engineered tumor-infiltrating lymphocyte (TIL) program, OBX-115, in its ongoing trials for patients with melanoma and non-small cell lung cancer (NSCLC). Obsidian Therapeutics is focused on enrolling patients and reaching key clinical and regulatory milestones, as well as manufacturing scale-up ahead of pivotal trial readiness.

By using this website you agree to accept Medical Device News Magazine Privacy Policy